TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

Exclusion Criteria

• •Acute coronary syndrome, stroke/transient ischemic attack, or coronary revascularization within 6 months before screening.
• •New York Heart Association (NYHA) class III-IV heart failure or left ventricular ejection fraction \<35%.
• •Clinically significant arrhythmia requiring recent hospitalization or unstable antiarrhythmic therapy.
• •Severe renal impairment (eGFR \<30 mL/min/1.73 m\^2) or end-stage renal disease.
• •Clinically significant hepatic impairment (e.g., Child-Pugh class B/C) or ALT/AST \>3x upper limit of normal at screening.
• •Active malignancy requiring systemic therapy (except adequately treated non-melanoma skin cancer) within the past 2 years.
• •Known autoimmune disease requiring systemic immunosuppression, or use of chronic systemic corticosteroids above physiologic replacement.
• •Pregnant or breastfeeding, or unwilling to use effective contraception during the study (if of childbearing potential).
• •Known hypersensitivity to peptide therapeutics or study formulation components.
• •Participation in another interventional clinical study or receipt of an investigational product within 30 days (or 5 half-lives, whichever is longer) prior to screening.